IN VITRO SCREENING & EVALUATION OF CHEMICALS

体外筛选

• 批准号: 6094199
• 负责人: RICHARD J SAN
• 金额: $ 5.43万
• 依托单位: MAGENTA CORPORATION
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-09-30 至 2002-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6094199
• 关键词: Salmonella typhimurium; carcinogen testing; drug screening /evaluation; human tissue; laboratory mouse; lymphoma; mutagen testing; urine

The contractor shall test under Good Laboratory Practice approximately 20 - 25 NCI-supplied and coded samples per year for their ability to induce mutations in the mouse lymphoma assays. Up to 5 samples per year will not be coded samples of chemical compounds but will be human urine specimens (single or pooled specimens). The contractor shall also test under Good Laboratory Practices, approximately 20 - 25 NCI-supplied and coded samples per year for their ability to induce mutations in Salmonella Typhimurium. Up to 5 samples per year will not be coded samples of chemical compounds but will be human urine specimens (single or pooled specimens).

承包商应根据药物非临床研究质量管理规范进行试验， 每年20 - 25份NCI提供和编码的样本， 在小鼠淋巴瘤测定中诱导突变。每年最多5个样本 将不是化学化合物的编码样本，而是人类尿液 样本（单个或合并样本）。 承包商还应测试 根据药物非临床研究质量管理规范，大约20 - 25个NCI供应的和 每年编码样本，以确定其诱导突变的能力， 鼠伤寒沙门氏菌。 每年最多5个样本将不会编码 化学化合物样本，但将是人类尿液样本（单个 或合并的样本）。